References
Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerre T, Xavier LL, Vittecoq O, Goupille P, Mulleman D, Paintaud G (2014) Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 2014(16):12509
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 25(6):1700–1721
Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P (2009) Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 137(5):1628–1640
Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468. doi:10.1001/jama.2011.406
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921–926
Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739–1745. doi:10.1136/ard.2008.092833
West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ (2008) Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 28(9):1122–1126
Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211–1228. doi:10.1007/s00228-009-0718-4
Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523–529
Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G (2012) Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 73(1):55–65
Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H (2008) Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48(6):681–695
Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G (2006) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 28(2):169–174
Acknowledgments
Measurements of adalimumab serum concentrations were carried out within the CePiBAc platform. CePiBAc was cofinanced by the European Union. Europe is committed to the region Centre with the European Regional Development Fund. This work was partly supported by the French Higher Education and Research ministry under the program ‘Investissements d’avenir’ Grant Agreement: LabEx MAbImprove ANR-10-LABX-53–01. The authors thank Anne-Claire Duveau and Caroline Brochon for technical assistance with adalimumab assays.
Authors’ contribution
D. Ternant participated actively in execution of the study, analyzed and interpreted the data, and wrote the manuscript.
K. Karmiris, G. Van Assche, and S. Vermeire conceived the ideas and experimental design and participated actively in execution of the study.
C. Desvignes participated actively in execution of the study.
N. Azzopardi participated actively in execution of the study and to the analysis of the data.
T. Bejan-Angoulvant participated to the analysis of the data.
G. Paintaud participated to the conception of the ideas and experimental design, and participated actively in execution of the study, to the analysis and interpretation of the data, and to the writing of the manuscript.
Conflict of interest
K. Karmiris reports personal fees from Abbvie and MSD outside the submitted work.
S. Vermeire reports grants and personal fees from UCB Pharma, Abbvie, Merck, and J&J and personal fees from Pfizer, Genentech/Roche, Takeda, Ferring, Celltrion, Mundipharma, Hospira, and Shire during the conduct of the study.
G. van Assche reports reports and Consultancy and/or honoraria from the following: Abbvie, Takeda, MSD, Janssen, and Falk. Research support to University of Leuven was from Abbvie.
G. Paintaud reports grants from Novartis, Roche Pharma, Genzyme, MSD, Servier, and Pfizer outside the submitted work.
D. Ternant, C. Desvignes, N. Azzopardi, and T. Bejan-Angoulvant declare that they have no competing interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Konstantinos Karmiris is the Principal investigator.
Rights and permissions
About this article
Cite this article
Ternant, D., Karmiris, K., Vermeire, S. et al. Pharmacokinetics of adalimumab in Crohn’s disease. Eur J Clin Pharmacol 71, 1155–1157 (2015). https://doi.org/10.1007/s00228-015-1892-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-015-1892-1